AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16617756 — intervention group
Group type: EXPERIMENTAL
Intervention: levobupivacaine + 3.3 microg sufentanil
Number of subjects: 91
Study 16617756 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine
Number of subjects: 91
Study 14739715 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0
Study 14739715 — intervention group
Group type: COMPARATOR
Intervention: Propafenone/Sotalol
Number of subjects: 0
Study 10812893 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) at 4 Hz
Number of subjects: 10
Study 10812893 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) at 8 Hz
Number of subjects: 10
Study 10812893 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) at 4 Hz and 8 Hz with food intake (solid meal 80 g, 135 cm3, 400 kcal)
Number of subjects: 10
Study 10812893 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) during food intake
Number of subjects: 10
Study 10812893 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 10
Study 8792887 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 micrograms/kg neostigmine at 25% TH
Number of subjects: 54
Study 8792887 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 micrograms/kg neostigmine at 50% TH
Number of subjects: 54
Study 8792887 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 micrograms/kg neostigmine at 10% TH
Number of subjects: 54
Study 1569672 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 gm cefonicid
Number of subjects: 107
Study 1569672 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 107
Study 3904243 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (50 mg b.i.d)
Number of subjects: 80
Study 3904243 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (200 mg t.i.d. + 400 mg nocte)
Number of subjects: 80
Study 31271261 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic product (1.5 × 10^10 CFU/day) consisting of Lactobacillus acidophilus DDS‐1, Bifidobacterium animalis subsp. lactis UABla‐12, Bifidobacterium longum UABl‐14, and Bifidobacterium bifidum UABb‐10 over 4 weeks
Number of subjects: 94
Study 31271261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 30032120 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacunar stroke patients
Number of subjects: 234
Study 30032120 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacunar stroke patients (3-month mRS 2-4)
Number of subjects: 234
Study 30032120 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacunar stroke patients (examining BI and RMI)
Number of subjects: 234
Study 27568199 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic meal (Ketonformula®) containing 20 g of MCTs
Number of subjects: 19
Study 27568199 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric placebo meal without MCTs
Number of subjects: 19
Study 25294887 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin-based chemotherapy (CT)
Number of subjects: 819
Study 25294887 — intervention group
Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 819
Study 22574584 — intervention group
Group type: EXPERIMENTAL
Intervention: Puerarin (0.5 g in 250 mL glucose injection, intravenously once daily for 14 days starting from the 3rd day)
Number of subjects: 54
Study 22574584 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine treatment only)
Number of subjects: 54
Study 20392594 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency right prefrontal rTMS (10Hz, 110% of motor threshold, 4s per train, 20 trains per session)
Number of subjects: 42
Study 20392594 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency right prefrontal rTMS
Number of subjects: 42
Study 20392594 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 42
Study 17003527 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole comedication
Number of subjects: 20
Study 17003527 — intervention group
Group type: COMPARATOR
Intervention: No itraconazole comedication
Number of subjects: 20
Study 15748091 — intervention group
Group type: EXPERIMENTAL
Intervention: Sivelestat (0.20 mg/kg/h)
Number of subjects: 0
Study 15748091 — intervention group
Group type: COMPARATOR
Intervention: Control (0.004 mg/kg/h, effectively a placebo)
Number of subjects: 0
Study 12141718 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 60 mg/pseudoephedrine 120 mg
Number of subjects: 298
Study 12141718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study 9928802 — intervention group
Group type: EXPERIMENTAL
Intervention: Different brands of tape for patch tests with 2 mg/cm2 sodium dodecyl sulfate (SLS) applied for 24 hours.
Number of subjects: 10
Study 7762544 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.8 mg, s.c.)
Number of subjects: 20
Study 7762544 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 20
Study 7762544 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone administration in healthy subjects
Number of subjects: 20
Study 7762544 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone administration in opiate-dependent patients
Number of subjects: 20
Study 7762544 — intervention group
Group type: EXPERIMENTAL
Intervention: Opiate withdrawal in patients
Number of subjects: 20
Study 7762544 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects receiving naloxone
Number of subjects: 20
Study 2306419 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0
Study 2306419 — intervention group
Group type: COMPARATOR
Intervention: Control (no cimetidine)
Number of subjects: 0
Study 374161 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release aminophylline
Number of subjects: 20
Study 374161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31111923 — intervention group
Group type: EXPERIMENTAL
Intervention: Dryland rearing on netting floors (DRNF)
Number of subjects: 2280
Study 31111923 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2280
Study 28089469 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbed sutures (Stratafix, Ethicon Inc)
Number of subjects: 109
Study 28089469 — intervention group
Group type: COMPARATOR
Intervention: Traditional sutures (Vicryl, Ethicon Inc)
Number of subjects: 109
Study 25503549 — intervention group
Group type: EXPERIMENTAL
Intervention: Expiratory training (n=27)
Number of subjects: 82
Study 25503549 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory training (n=26)
Number of subjects: 82
Study 25503549 — intervention group
Group type: COMPARATOR
Intervention: Sham training (n=25)
Number of subjects: 82
Study 25503549 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 82
Study 21867595 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial oocyte activation (AOA)
Number of subjects: 386
Study 21867595 — intervention group
Group type: COMPARATOR
Intervention: Controlled group
Number of subjects: 386
Study 20559144 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 8
Study 20559144 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 8
Study 19752319 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone 400 mg BID
Number of subjects: 4628
Study 19752319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4628
Study 17087362 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (500 mg/day)
Number of subjects: 165
Study 17087362 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (10 mg/day)
Number of subjects: 165
Study 17087362 — intervention group
Group type: COMPARATOR
Intervention: Patients with HCV infection
Number of subjects: 165
Study 17087362 — intervention group
Group type: COMPARATOR
Intervention: Patients without HCV infection
Number of subjects: 165
Study 17087362 — intervention group
Group type: COMPARATOR
Intervention: C. pneumoniae infection and anti‐HCV positivity
Number of subjects: 165
Study 15311722 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulphate capsules (50 mg zinc)
Number of subjects: 30
Study 15311722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11399959 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole prophylaxis
Number of subjects: 0
Study 11399959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9118759 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral erythromycin (250 mg t.i.d.)
Number of subjects: 12
Study 8101050 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV + gastrojejunostomy
Number of subjects: 90
Study 8101050 — intervention group
Group type: COMPARATOR
Intervention: HSV + Jaboulay gastroduodenostomy
Number of subjects: 90
Study 8101050 — intervention group
Group type: COMPARATOR
Intervention: SV + antrectomy
Number of subjects: 90
Study 2880872 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 24
Study 2880872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31666093 — intervention group
Group type: EXPERIMENTAL
Intervention: Study personnel strategies for patient recruitment
Number of subjects: 148
Study 31666093 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to recruitment
Number of subjects: 148
Study 29931604 — intervention group
Group type: COMPARATOR
Intervention: 0.5% body weight (BW) supplementation
Number of subjects: 12
Study 29931604 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% body weight (BW) supplementation
Number of subjects: 12
Study 29931604 — intervention group
Group type: EXPERIMENTAL
Intervention: Both supplementation levels
Number of subjects: 12
Study 27146213 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam 150-200 mg/day
Number of subjects: 0
Study 27146213 — intervention group
Group type: COMPARATOR
Intervention: Coadministration with carbamazepine
Number of subjects: 0
Study 27146213 — intervention group
Group type: COMPARATOR
Intervention: Coadministration with phenytoin
Number of subjects: 0
Study 27146213 — intervention group
Group type: COMPARATOR
Intervention: Coadministration with phenobarbital
Number of subjects: 0
Study 27146213 — intervention group
Group type: COMPARATOR
Intervention: Coadministration with levetiracetam
Number of subjects: 0
Study 27146213 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline seizure frequency
Number of subjects: 0
Study 25229983 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin-based triple therapy (omeprazole 20 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily for 10 days)
Number of subjects: 111
Study 25229983 — intervention group
Group type: COMPARATOR
Intervention: Empirical triple therapy (omeprazole 20 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily for 10 days)
Number of subjects: 111
Study 22579427 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Thai massage (TTM)
Number of subjects: 40
Study 22579427 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy (PT)
Number of subjects: 40
Study 20459600 — intervention group
Group type: EXPERIMENTAL
Intervention: Soap + low pressure
Number of subjects: 2280
Study 20459600 — intervention group
Group type: EXPERIMENTAL
Intervention: Soap + gravity flow pressure
Number of subjects: 2280
Study 20459600 — intervention group
Group type: EXPERIMENTAL
Intervention: Soap + high pressure
Number of subjects: 2280
Study 20459600 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline + low pressure
Number of subjects: 2280
Study 20459600 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline + gravity flow pressure
Number of subjects: 2280
Study 20459600 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline + high pressure
Number of subjects: 2280
Study 20459600 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 2280
Study 18753638 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus extended-release dipyridamole (ASA-ERDP) 25 mg + 200 mg twice daily
Number of subjects: 20332
Study 18753638 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg daily
Number of subjects: 20332
Study 18753638 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus extended-release dipyridamole (ASA-ERDP)
Number of subjects: 20332
Study 18753638 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 20332
Study 16113753 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromogenic assay for functional determination of TFPI
Number of subjects: 7000
Study 12418644 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic with protected lactobacilli
Number of subjects: 740
Study 12418644 — intervention group
Group type: COMPARATOR
Intervention: Plain antibiotic (ampicillin 250 mg and cloxacillin 250 mg)
Number of subjects: 740
Study 10343624 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (1500 micrograms beclomethasone daily, 1600 micrograms budesonide daily, 800 micrograms beclomethasone daily)
Number of subjects: 183
Study 10343624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 7555480 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy (multiple daily injections (MDI) of insulin or continuous subcutaneous insulin infusion (CSII))
Number of subjects: 1441
Study 7555480 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 1441
Study 7555480 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 1441
Study 7555480 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI
Number of subjects: 1441
Study 7555480 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 1441
Study 2037265 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline 1 mg p.o. (n = 18)
Number of subjects: 36
Study 2037265 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine 5 mg/day p.o. for 14 days (n = 18)
Number of subjects: 36
Study 30265024 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation (24 hours)
Number of subjects: 234
Study 30265024 — intervention group
Group type: COMPARATOR
Intervention: Control group (participants who slept at home)
Number of subjects: 234
Study 28716215 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio‐Gide collagen membrane (experimental group)
Number of subjects: 43
Study 28716215 — intervention group
Group type: COMPARATOR
Intervention: No collagen membrane (control group)
Number of subjects: 43
Study 26536327 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 187
Study 26536327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 26536327 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 187
Study 24117655 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor performance (Finger Tapping Test)
Number of subjects: 280
Study 24117655 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive performance (Trail Making Test)
Number of subjects: 280
Study 24117655 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath alcohol concentration (BrAC)
Number of subjects: 280
Study 24117655 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-related stimulant effects
Number of subjects: 280
Study 24117655 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-related sedative effects
Number of subjects: 280
Study 21727728 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 160
Study 21727728 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 160
Study 19723863 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% solution chlorhexidine oral swab twice daily
Number of subjects: 547
Study 19723863 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrushing thrice daily
Number of subjects: 547
Study 19723863 — intervention group
Group type: EXPERIMENTAL
Intervention: Both toothbrushing and chlorhexidine
Number of subjects: 547
Study 19723863 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 547
Study 17727664 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% mannitol (1.5 g/kg)
Number of subjects: 24
Study 17727664 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study 15128353 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-IFN alpha2a (180 microg/wk) and ribavirin (1-1.2 g/d) with addition of 200 mg amantadine
Number of subjects: 6
Study 15128353 — intervention group
Group type: COMPARATOR
Intervention: PEG-IFN alpha2a (180 microg/wk) and ribavirin (1-1.2 g/d) with placebo
Number of subjects: 6
Study 11490709 — intervention group
Group type: EXPERIMENTAL
Intervention: Categel (sterile gel of methylcellulose with 2% lidocaine and 0.05% chlorhexidine)
Number of subjects: 0
Study 11490709 — intervention group
Group type: EXPERIMENTAL
Intervention: Categel S (contains the same components but without lidocaine)
Number of subjects: 0
Study 11490709 — intervention group
Group type: EXPERIMENTAL
Intervention: Categel
Number of subjects: 0
Study 11367659 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated traditional Chinese and Western medicine (TCM‐WM)
Number of subjects: 83
Study 11367659 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 83
Study 7802064 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-cerebral-to-umbilical-artery ratio cutoff value of 1.0
Number of subjects: 135
Study 7802064 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy women with uncomplicated singleton pregnancies)
Number of subjects: 135
Study 3042644 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine 10 mg orally daily for three months
Number of subjects: 0
Study 3042644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31594037 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib (3, 6, 12, 24 mg b.i.d. or 24 mg q.d.)
Number of subjects: 216
Study 31594037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 29605825 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemonade (2 mEq/kg/day citrate) for 5 days
Number of subjects: 126
Study 29605825 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate (2 mEq/kg/day) for 5 days
Number of subjects: 126
Study 27537364 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 80
Study 27537364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 27537364 — intervention group
Group type: EXPERIMENTAL
Intervention: Reappraisal
Number of subjects: 80
Study 27537364 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory stimulation
Number of subjects: 80
Study 23731019 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (80 mg for 4 weeks, then 160 mg for 20 weeks)
Number of subjects: 95
Study 23731019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 22725606 — intervention group
Group type: EXPERIMENTAL
Intervention: Thickened preterm formula (TPF)
Number of subjects: 28
Study 22725606 — intervention group
Group type: COMPARATOR
Intervention: Preterm formula (PF)
Number of subjects: 28
Study 20357044 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg trans-resveratrol
Number of subjects: 22
Study 20357044 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg trans-resveratrol
Number of subjects: 22
Study 20357044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 18372278 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg)
Number of subjects: 17
Study 18372278 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg) plus Spironolactone (25 mg)
Number of subjects: 17
Study 18372278 — intervention group
Group type: COMPARATOR
Intervention: Control (no medications)
Number of subjects: 17
Study 15992642 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance imaging (CMR)
Number of subjects: 235
Study 15992642 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers and athletes)
Number of subjects: 235
Study 12881382 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 167
Study 12881382 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 167
Study 12881382 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) in postmenopausal patients
Number of subjects: 167
Study 12881382 — intervention group
Group type: COMPARATOR
Intervention: Observation in premenopausal women
Number of subjects: 167
Study 12881382 — intervention group
Group type: COMPARATOR
Intervention: Observation in premenopausal patients
Number of subjects: 167
Study 12881382 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) in premenopausal patients
Number of subjects: 167
Study 10579148 — intervention group
Group type: EXPERIMENTAL
Intervention: rBPI21 30-minute infusion at doses of 0.25 to 4 mg/kg
Number of subjects: 0
Study 10579148 — intervention group
Group type: EXPERIMENTAL
Intervention: rBPI21 24- to 48-hour infusion at doses of 2 to 8 mg/kg
Number of subjects: 0
Study 10579148 — intervention group
Group type: EXPERIMENTAL
Intervention: Model for clearance of rBPI21
Number of subjects: 0
Study 8743521 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (10 to 40 mg/day)
Number of subjects: 13
Study 8743521 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5 to 20 mg/day)
Number of subjects: 13
Study 8743521 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 13
Study 8743521 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 13
Study 1959070 — intervention group
Group type: EXPERIMENTAL
Intervention: CPEP services (n = 97)
Number of subjects: 191
Study 1959070 — intervention group
Group type: COMPARATOR
Intervention: Traditional community services (n = 94)
Number of subjects: 191
Study 6803288 — intervention group
Group type: EXPERIMENTAL
Intervention: + tranylcypromine
Number of subjects: 0
Study 6803288 — intervention group
Group type: EXPERIMENTAL
Intervention: - tranylcypromine
Number of subjects: 0
Study 6803288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29578820 — intervention group
Group type: EXPERIMENTAL
Intervention: MSHC with ACP to the moving arm
Number of subjects: 39